gastric cancer
Agilent Gains IVDR Certification for Expanded Use of CDx Assay for Keytruda
The PD-L1 IHC 22C3 PharmDx (Code SK006) assay is now certified for use to aid treatment decisions for patients with gastric or gastroesophageal junction adenocarcinoma.
AstraZeneca, Daiichi Sankyo Begin First-Line Trial of Enhertu, Keytruda Combo in Gastric Cancer
The trial will include patients with locally advanced or metastatic HER2-positive, PD-L1-positive gastric or gastroesophageal junction cancer.
The firms hope to show that Verdi's off-the-shelf peptide cancer vaccine can shrink tumors and improve quality of life in patients with bone metastases.
Elevation Oncology Terminates CLDN18.2-Targeted ADC, Reduces Workforce
The company said initial efficacy results from a Phase I trial did not provide a competitive benefit-risk profile in CLDN18.2-positive gastric and gastroesophageal cancer.
I-Mab Advances Phase Ib Trial of Givastomig in CLDN18.2-Expressing Gastric Cancers
The firm completed enrollment of the first dose expansion cohort evaluating givastomig with immunotherapy and chemotherapy.